SynthesisCurrent pharmaceutical design2012
Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies.
Synthesis in Current pharmaceutical design, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cannabis use and psychosis: a review of reviews.European archives of psychiatry and clinical neuroscience · 2020Pooled it
- Effects of cannabis on impulsivity: a systematic review of neuroimaging findings.Current pharmaceutical design · 2014Pooled it
- Neuroanatomical heterogeneity and homogeneity in individuals at clinical high risk for psychosis.Translational psychiatry · 2022Article
- Pattern of predictive features of continued cannabis use in patients with recent-onset psychosis and clinical high-risk for psychosis.Schizophrenia (Heidelberg, Germany) · 2022Article
- Total Brain Volumetric Measures and Schizophrenia Risk: A Two-Sample Mendelian Randomization Study.Frontiers in genetics · 2022Article
- The Link Between Cannabis Use and Violent Behavior in the Early Phase of Psychosis: The Potential Role of Impulsivity.Frontiers in psychiatry · 2022Article
- Eye movements in patients in early psychosis with and without a history of cannabis use.NPJ schizophrenia · 2021Article
- Early onset of cannabis use and violent behavior in psychosis.European psychiatry : the journal of the Association of European Psychiatrists · 2020Article
- Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach.Scientific reports · 2019Article
- Are structural brain changes in schizophrenia related to antipsychotic medication? A narrative review of the evidence from a clinical perspective.Therapeutic advances in psychopharmacology · 2018Review
- Fronto-striatal effective connectivity of working memory in adults with cannabis use disorder.Psychiatry research. Neuroimaging · 2018Article
- Associations between adolescent cannabis use and brain structure in psychosis.Psychiatry research. Neuroimaging · 2018Article
- Aberrant cerebellar connectivity in bipolar disorder with psychosis.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2017Article
- The Impact of CB2 Receptor Ligands on the MK-801-Induced Hyperactivity in Mice.Neurotoxicity research · 2017Article
- Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia.Molecular neurobiology · 2017Review
- Lifetime use of cannabis from longitudinal assessments, cannabinoid receptor (CNR1) variation, and reduced volume of the right anterior cingulate.Psychiatry research. Neuroimaging · 2016Article
- Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History.PloS one · 2016Article
- Lack of Evidence for Regional Brain Volume or Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings From the Longitudinal Youth at Risk Study.Schizophrenia bulletin · 2015Article
- Safety and Toxicology of Cannabinoids.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Review
- The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability.Frontiers in psychiatry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is unclear yet whether cannabis use is a moderating or causal factor contributing to grey matter alterations in schizophrenia and the development of psychotic symptoms. We therefore systematically reviewed structural brain imaging and post mortem studies addressing the effects of cannabis use on brain structure in psychosis. Studies with schizophrenia (SCZ) and first episode psychosis (FEP) patients as well as individuals at genetic (GHR) or clinical high risk for psychosis (ARMS) were included. We identified 15 structural magnetic resonance imaging (MRI) (12 cross sectional / 3 longitudinal) and 4 post mortem studies. The total number of subjects encompassed 601 schizophrenia or first episode psychosis patients, 255 individuals at clinical or genetic high risk for psychosis and 397 healthy controls. We found evidence for consistent brain structural abnormalities in cannabinoid 1 (CB1) receptor enhanced brain areas as the cingulate and prefrontal cortices and the cerebellum. As these effects have not consistently been reported in studies examining nonpsychotic and healthy samples, psychosis patients and subjects at risk for psychosis might be particularly vulnerable to brain volume loss due to cannabis exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.